Loading...

Nutriband Inc.

NTRBNASDAQ
Healthcare
Biotechnology
$6.95
$-0.18(-2.52%)

Nutriband Inc. (NTRB) Company Profile & Overview

Explore Nutriband Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Nutriband Inc. (NTRB) Company Profile & Overview

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

SectorHealthcare
IndustryBiotechnology
CEOGareth Sheridan

Contact Information

407 377 6695
121 South Orange Avenue, Orlando, FL, 32801

Company Facts

13 Employees
IPO DateOct 1, 2021
CountryUS
Actively Trading

Frequently Asked Questions

;